HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice

Vaccine

Volumn 30, Issue 1, 2011, Pages 42-50

  Zaharatos, Gerasimos J ^a   Yu, Jian ^a   Pace, Craig ^a   Song, Yang ^a   Vasan, Sandhya ^a   Ho, David D ^a   Huang, Yaoxing ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Fc receptors; Immunoglobulin G; Vaccine

Indexed keywords

DNA VACCINE; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HIV-1; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS;

EID: 84858591135     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.056     Document Type: Article

References (71)

1. DeFranco AL, Locksley RM, Robertson M. B cells and humoral immunity. In: Freeland K, editor. Immunity: The Immune Response in Infectious and Inflammatory Disease. 1st ed. London: New Science Press; 2007. p. 153-79.
2. Schroeder HW, Wald D, Greenspan NS. Immunoglobulins: structure and function. In: Paul WE, editor. Fundamental Immunology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 125-51.
3. Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M, et al. Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol 2008;180:1948-53.
4. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 2006;24:19-28.
5. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005;23:41-51.
6. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90.
7. El Shikh Mohey E, El Sayed R, Szakal Andras K, Tew John G. Follicular dendritic cell (FDC)-FcγRIIB engagement via immune complexes induces the activated FDC phenotype associated with secondary follicle development. Eur J Immunol 2006;36:2715-24.
8. Qin D, Wu J, Vora KA, Ravetch JV, Szakal AK, Manser T, et al. Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol 2000;164:6268-75.
9. Fanger NA, Wardwell K, Shen L, Tedder TF, Guyre PM. Type I. (CD64) and type II (CD32) Fcγ receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996;157:541-8.
10. Amigorena S, Lankar D, Briken V, Gapin L, Viguier M, Bonnerot C. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens. J Exp Med 1998;187:505-15.
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
12. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
13. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med 2002;195:1653-9.
14. Liu Y, Gao X, Masuda E, Redecha PB, Blank MC, Pricop L. Regulated expression of FcγR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J Immunol 2006;177:8440-7.
15. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
16. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999;189: 179-85.
17. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005;102:2910-5.
18. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005;115:2914-23.
19. Hamano Y, Arase H, Saisho H, Saito T. Immune complex and Fc receptormediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol 2000;164:6113-9.
20. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
21. Getahun A, Dahlstrom J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fcγ receptors. J Immunol 2004;172:5269-76.
22. Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. Fc[γ]RIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007;8:419-29.
23. Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010;10:328-43.
24. Barrionuevo P, Beigier-Bompadre M, Fernandez GC, Gomez S, Alves-Rosa MF, Palermo MS, et al. Immune complex-FcγR interaction modulates monocyte/ macrophage molecules involved in inflammation and immune response. Clin Exp Immunol 2003;133:200-7.
25. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69.
26. Brady LJ. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 2005;73:671-8.
27. Getahun A, Heyman B. How antibodies act as natural adjuvants. Immunol Lett 2006;104:38-45.
28. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, et al. A consensushemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 2008;105:13538-43.
29. Chen M-W, Liao H-Y, Huang Y, Jan J-T, Huang C-C, Ren C-T, et al. Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc Natl Acad Sci U S A 2011;108:3510-5.
30. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995;206:935-44.
31. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol 1995;155:1165-74.
32. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988;332:738-40.
33. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988;332: 563-4.
34. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
35. Billetta R, Hollingdale MR, Zanetti M. Immunogenicity of an engineered internal image antibody. Proc Natl Acad Sci U S A 1991;88:4713-7.
36. Zanetti M. Antigenized antibodies. Nature 1992;355:476-7.
37. Gascoigne NR, Goodnow CC, Dudzik KI, Oi VT, Davis MM. Secretion of a chimeric T-cell receptor-immunoglobulin protein. Proc Natl Acad Sci U S A 1987;84:2936-40.
38. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337: 525-31.
39. Traunecker A, Schneider J, Kiefer H, Karjalainen K. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989;339:68-70.
40. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, et al. Biological properties of a CD4 immunoadhesin. Nature 1990;344:667-70.
41. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
42. Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J Exp Med 1993;178:1795-9.
43. Cook J, Barber BH. Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses. Vaccine 1995;13:1770-8.
44. Corthesy B, Kaufmann M, Phalipon A, Peitsch M, Neutra MR, Kraehenbuhl JP. A pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route. J Biol Chem 1996;271: 33670-7.
45. Lanza P, Billetta R, Antonenko S, Zanetti M. Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain. Proc Natl Acad Sci U S A 1993;90:11683-7.
46. Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, et al. Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol 2011;85:3010-4.
47. Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, et al. A neonatal Fc receptortargeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol 2011;85:10542-53.
48. Rasmussen IB, Lunde E, Michaelsen TE, Bogen B, Sandlie I. The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination. Proc Natl Acad Sci U S A 2001;98:10296-301.
49. Xiong S, Gerloni M, Zanetti M. Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. Nat Biotechnol 1997;15:882-6.
50. Zaghouani H, Anderson SA, Sperber KE, Daian C, Kennedy RC, Mayer L, et al. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. Proc Natl Acad Sci U S A 1995;92:631-5.
51. Zhang M-Y, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009;27:857-63.
52. Ye L, Zeng R, Bai Y, Roopenian DC, Zhu X. Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol 2011;29:158-63.
53. Huang Y, Chen Z, Zhang W, Gurner D, Song Y, Gardiner DF, et al. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. JAIDS 2008;47:403-11.
54. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999;67:4780-6.
55. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25.
56. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001;13:1551-9.
57. Vieira P, Rajewsky K. The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half-life of 6-8 days. Eur J Immunol 1986;16:871-4.
58. Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 1988;18:313-6.
59. Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 2006;176:4573-80.
60. Vora K, Ravetch J, Manser T. Amplified follicular immune complex deposition in mice lacking the Fc receptor γ-chain does not alter maturation of the B cell response. J Immunol 1997;159:2116-24.
61. Wernersson S, Karlsson MC, Dahlstrom J, Mattsson R, Verbeek JS, Heyman B. IgG-mediated enhancement of antibody responses is low in Fc receptor γ chain-deficient mice and increased in FcγRII-deficient mice. J Immunol 1999;163:618-22.
62. Baudino L, Nimmerjahn F, Shinohara Y, Furukawa J, Petry F, Verbeek JS, et al. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 2008;181:4107-12.
63. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
64. Park CS, Choi YS. How do follicular dendritic cells interact intimately with B cells in the germinal centre? Immunology 2005;114:2-10.
65. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010;237:72-89.
66. Kosco-Vilbois MH. Are follicular dendritic cells really good for nothing? Nat Rev Immunol 2003;3:764-9.
67. El Shikh MEM, El Sayed RM, Sukumar S, Szakal AK, Tew JG. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol 2010;31:205-11.
68. Yoshida K, van den Berg TK, Dijkstra CD. Two functionally different follicular dendritic cells in secondary lymphoid follicles of mouse spleen, as revealed by CR1/2 and FcγRII-mediated immune-complex trapping. Immunology 1993;80:34-9.
69. Mandel TE, Phipps RP, Abbot A, Tew JG. The follicular dendritic cell: long term antigen retention during immunity. Immunol Rev 1980;53:29-59.
70. Heinen E, Coulie P, Van Snick J, Braun M, Cormann N, Moeremans M, et al. Retention of immune complexes by murine lymph node or spleen follicular dendritic cells. Role of antibody isotype. Scand J Immunol 1986;24: 327-34.
71. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, et al. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010;107:19396-401.